Business Wire

SUNET harnesses Adtran’s ALM fiber monitoring solution for national backbone network

28.5.2024 15:00:00 EEST | Business Wire | Press release

Share

Adtrantoday announced that the Swedish University Computer Network (SUNET) has deployed its ALM in-service fiber monitoring solution to enhance network resilience and operational efficiency. The technology equips SUNET’s maintenance teams with real-time insight into the quality of its nationwide backbone infrastructure and identifies the precise location of any fiber issues. As Sweden’s research and education (R&E) network, SUNET empowers academics and scientists across the country to access learning resources, conduct research and collaborate internationally. With the deployment of ALM, the Nordics’ R&E community has additional assurance of uninterrupted, high-quality services. NetNordic, a key technology partner of SUNET, was also involved in the deployment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528454910/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s ALM is helping SUNET monitor its national fiber network to rapidly identify faults and support swift resolution. (Photo: Business Wire)

“SUNET is a world-class high-capacity optical transport network connecting over 110 organizations and serving a community of 750,000 students, teachers and researchers across Sweden and beyond. The deployment of our ALM platform, with its passive fiber monitoring capabilities, has built even more resilience into this crucially important infrastructure, rendering services more reliable and streamlining operations,” said Stuart Broome, GM of EMEA sales at Adtran. “Finding the exact location of faults is a huge challenge for any operator. But now, with the ability to monitor the integrity of its fiber plant passively and proactively, SUNET’s maintenance teams no longer have to engage in costly and complicated post-failure analysis. ALM enables them to address issues before they impact the high-bandwidth, low-latency services Sweden’s R&E community relies on.”

The deployment of Adtran’s 16-port ALM fiber assurance solution across SUNET’s extensive fiber 8,000km backbone network enables rapid identification and resolution of failures, enhancing network resilience. This is a crucial advantage for a user community involved in data-heavy scientific research. The technology also helps improve efficiency by enabling proactive maintenance. Through an intuitive graphical user interface, SUNET can leverage ALM to monitor a vast national infrastructure containing RAMAN-amplified optical links. The platform detects abnormal attenuation, fiber breaks, tapping attempts and other issues that have the potential to impact connection quality and service availability. ALM also boosts sustainability by cutting down on truck rolls, while its low power use and fanless design ensure a greener, less resource-heavy network.

“From climate science to engineering to medicine, SUNET supports a wide range of important data-intensive projects. That’s why its infrastructure needs to be both fast and highly reliable. Our ALM technology guarantees peak network efficiency and resilience against unpredictable challenges like excavation damage or severe storms. With 24/7 monitoring capabilities, it enables SUNET’s maintenance teams to quickly identify and rectify any issues, ensuring uninterrupted, high-quality service,” commented Sander Jansen, GM of infrastructure monitoring at Adtran. “Moreover, our technology enhances environmental sustainability by reducing unnecessary site visits and lowering carbon footprint. This creates a network that benefits not just today’s users but also future generations.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

About SUNET

SUNET, the Swedish University Computer Network, has served the Swedish universities and other organizations closely related to research and education for more than 40 years. We provide the connected organizations with access to well-developed and effective national and international data communication, a national academic identity infrastructure and other related services that meet their needs, regardless of their geographical location. We are part of the Swedish Research Council and connect Sweden through 8400 km of nationwide dark fiber. For more information, please visit www.sunet.se.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye